Seattle Genetics cancer drug meets study goal - BusinessWeek

[INCIID News Feed]

Proactive Investors USA & Canada
<img alt="" height="1" width="1" />
Seattle Genetics cancer drug meets study goal
BusinessWeek
Seattle Genetics Inc. said Monday its potential cancer drug SGN-35 met key goals in a pivotal study. The company is testing the drug candidate as a potential treatment for Hodgkin&#39;s lymphoma. The study involved 102 patients, with 75 percent of the ...
Seattle Genetics, Takeda Drug Shrinks Lymphoma Patients&#39; Tumors in StudyBloomberg
Seattle Genetics reports success in lymphoma trialSeattle Times
Seattle Genetics Cancer Drug Passes TestTheStreet.com
RTT News -FierceBiotech -New York Times (blog)
all 50 news articles &raquo;


More...